AADI RSI Chart
Last 7 days
7.3%
Last 30 days
5.0%
Last 90 days
0.5%
Trailing 12 Months
-74.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 23.8M | 0 | 0 | 0 |
2023 | 18.8M | 21.5M | 23.3M | 24.4M |
2022 | 14.3M | 14.6M | 14.9M | 15.2M |
2021 | 14.0M | 14.0M | 14.0M | 14.0M |
2020 | 18.6M | 17.1M | 15.5M | 14.0M |
2018 | 0 | 6.8M | 13.5M | 20.2M |
2017 | 158.3K | 88.6K | 108.8K | 93.7K |
2016 | 310.1K | 250.5K | 190.9K | 131.3K |
2015 | 0 | 0 | 0 | 369.7K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 01, 2024 | desai neil | sold | -77,184 | 1.9296 | -40,000 | executive chairman |
Apr 02, 2024 | desai neil | sold | -49,512 | 2.2275 | -22,228 | executive chairman |
Apr 01, 2024 | desai neil | sold | -41,101 | 2.3127 | -17,772 | executive chairman |
Mar 04, 2024 | desai neil | sold | -31,415 | 2.0994 | -14,964 | executive chairman |
Mar 01, 2024 | desai neil | sold | -53,225 | 1.9687 | -27,036 | executive chairman |
Feb 01, 2024 | desai neil | sold | -73,269 | 1.7445 | -42,000 | executive chairman |
Jan 02, 2024 | desai neil | sold | -86,549 | 2.0607 | -42,000 | executive chairman |
Dec 06, 2023 | desai neil | sold | -33,914 | 4.8194 | -7,037 | executive chairman |
Dec 05, 2023 | desai neil | sold | -78,940 | 5.0153 | -15,740 | executive chairman |
Dec 04, 2023 | desai neil | sold | -55,986 | 5.1477 | -10,876 | executive chairman |
Which funds bought or sold AADI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -31.01 | -1,083 | 4,310 | -% |
May 15, 2024 | 683 Capital Management, LLC | unchanged | - | 64,000 | 468,000 | 0.03% |
May 15, 2024 | BARCLAYS PLC | reduced | -48.99 | -18,000 | 27,000 | -% |
May 15, 2024 | AMERIPRISE FINANCIAL INC | sold off | -100 | -209,048 | - | -% |
May 15, 2024 | MERCER GLOBAL ADVISORS INC /ADV | sold off | -100 | -37,000 | - | -% |
May 15, 2024 | JACOBS LEVY EQUITY MANAGEMENT, INC | sold off | -100 | -62,372 | - | -% |
May 15, 2024 | ABG Innovation Capital Partners III GP Ltd | unchanged | - | 8,533 | 62,398 | 7.50% |
May 15, 2024 | Schonfeld Strategic Advisors LLC | unchanged | - | 13,344 | 97,578 | -% |
May 15, 2024 | Lion Point Capital, LP | sold off | -100 | -166,494 | - | -% |
May 15, 2024 | Squarepoint Ops LLC | sold off | -100 | -93,251 | - | -% |
Unveiling Aadi Bioscience, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Aadi Bioscience, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Aadi Bioscience, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | -15.4% | 5,353,000 | 6,326,000 | 5,959,000 | 6,202,000 | 5,867,000 | 5,227,000 | 4,245,000 | 3,437,000 | 2,307,000 | - | - | - | - | - | - | - | 15,000,000 | 7,501,072 | 2,144 | 18,821,953 | 1,333,333 |
Costs and Expenses | 3.4% | 24,865,000 | 24,040,000 | 23,808,000 | 25,747,000 | 22,692,000 | 20,698,500 | 19,281,000 | 21,797,000 | 16,121,000 | 16,944,500 | - | 87,311,000 | 3,875,000 | 4,207,000 | - | - | - | - | - | - | - |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | 15,798,388 | - | 87,311,000 | 4,771,361 | 5,602,863 | 5,060,490 | 2,894,000 | 5,744,087 | 4,114,933 | 8,868,322 | 7,623,916 | 7,369,788 |
S&GA Expenses | 2.7% | 10,620,000 | 10,345,000 | 11,221,000 | 11,776,000 | 11,207,000 | 11,107,000 | 9,915,000 | 10,006,000 | 9,148,000 | 9,717,500 | - | 7,401,000 | 830,000 | 563,000 | -1,219,203 | 499,000 | 2,195,515 | 2,285,891 | 3,619,692 | 3,277,535 | 3,140,854 |
R&D Expenses | 6.5% | 13,593,000 | 12,768,000 | 11,890,000 | 13,315,000 | 10,956,000 | 9,369,500 | 8,773,000 | 7,726,000 | 6,794,000 | 7,227,000 | - | 5,754,000 | 3,045,000 | 3,644,000 | 6,279,693 | 2,395,000 | 3,548,572 | 1,829,042 | 5,248,630 | 4,346,381 | 4,228,934 |
EBITDA Margin | -2.1% | -2.69 | -2.63 | -2.68 | -2.98 | -3.20 | -3.95 | -4.17 | -9.22 | -8.23 | -7.81 | -0.19 | -0.19 | -0.18 | - | - | - | - | - | - | - | - |
Interest Expenses | 1.8% | 58,000 | 57,000 | 58,000 | 58,000 | 58,000 | 56,500 | 58,000 | 58,000 | 58,000 | 57,000 | - | 157,000 | 227,000 | 224,000 | 230,000 | 229,000 | - | - | - | - | - |
Income Taxes | - | - | - | - | - | - | -9,000 | - | 9,000 | - | - | - | - | 2,000 | - | - | 1,000 | - | - | - | - | - |
Earnings Before Taxes | 100.0% | - | -16,269,000 | -16,302,000 | -17,971,000 | - | -13,922,000 | -14,474,000 | -18,260,000 | -13,857,000 | -15,990,000 | - | -87,088,000 | -1,534,000 | -5,476,000 | - | -2,891,000 | - | - | - | - | - |
EBT Margin | -2.2% | -2.70 | -2.65 | -2.69 | -3.00 | -3.22 | -3.98 | -4.20 | -9.25 | -8.28 | -7.86 | -0.25 | -0.25 | -0.25 | - | - | - | - | - | - | - | - |
Net Income | -12.4% | -18,289,000 | -16,269,000 | -16,302,000 | -17,971,000 | -15,223,000 | -13,913,000 | -14,474,000 | -18,269,000 | -13,857,000 | -15,990,000 | - | -87,088,000 | -1,536,000 | -5,476,000 | 8,020,000 | -2,892,000 | -5,282,000 | -3,324,000 | -8,518,590 | 11,537,478 | -5,989,992 |
Net Income Margin | -6.9% | -2.89 | -2.70 | -2.73 | -2.86 | -3.30 | -3.98 | -4.20 | -9.26 | -8.28 | -7.86 | -6.15 | -6.15 | -0.13 | - | - | - | - | - | - | - | - |
Free Cashflow | -95.0% | -20,392,000 | -10,460,000 | -13,049,000 | -17,447,000 | -22,679,000 | -11,388,000 | -8,297,000 | -10,961,000 | -19,438,000 | -12,474,000 | -17,373,000 | -17,373,000 | -3,185,000 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -16.1% | 111 | 132 | 140 | 151 | 171 | 184 | 194 | 129 | 142 | 158 | 169 | 37.00 | 41.00 | 19.00 | 50.00 | 46.00 | 36.00 | 40.00 | 46.00 | 50.00 | 55.00 |
Current Assets | -17.7% | 103 | 125 | 133 | 145 | 165 | 180 | 190 | 124 | 136 | 151 | 162 | 37.00 | 41.00 | 19.00 | 50.00 | 45.00 | 35.00 | 40.00 | 45.00 | 49.00 | 54.00 |
Cash Equivalents | -14.5% | 54.00 | 63.00 | 69.00 | 68.00 | 34.00 | 39.00 | 135 | 119 | 130 | 149 | 161 | 37.00 | 39.00 | 4.00 | 47.00 | 45.00 | 35.00 | 39.00 | 43.00 | 48.00 | 53.00 |
Inventory | -7.6% | 6.00 | 6.00 | 4.00 | 3.00 | 4.00 | 2.00 | 1.00 | 1.00 | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | 18.4% | 6.00 | 5.00 | 4.00 | 3.00 | 2.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | -24.3% | 21.00 | 27.00 | 21.00 | 20.00 | 25.00 | 26.00 | 25.00 | 20.00 | 18.00 | 22.00 | 18.00 | 2.00 | 2.00 | 31.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 4.00 |
Current Liabilities | -24.7% | 20.00 | 26.00 | 21.00 | 13.00 | 18.00 | 19.00 | 18.00 | 13.00 | 12.00 | 15.00 | 12.00 | 2.00 | 2.00 | 30.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 4.00 |
Shareholder's Equity | -14.0% | 90.00 | 105 | 118 | 131 | 146 | 158 | 169 | 109 | 125 | 136 | 151 | 35.00 | 39.00 | 43.00 | 47.00 | 43.00 | 33.00 | 37.00 | 42.00 | 46.00 | 51.00 |
Retained Earnings | -6.8% | -287 | -269 | -252 | -236 | -218 | -203 | -189 | -174 | -156 | -142 | -126 | -155 | -150 | -32.59 | -141 | -136 | -146 | -142 | -137 | -133 | -127 |
Additional Paid-In Capital | 1.0% | 378 | 374 | 371 | 368 | 364 | 362 | 358 | 284 | 281 | 279 | 278 | 191 | 190 | 20.00 | 189 | 179 | 179 | 179 | 179 | 179 | 178 |
Shares Outstanding | 0% | 25.00 | 25.00 | 25.00 | 25.00 | 24.00 | 24.00 | 21.00 | 21.00 | 21.00 | 21.00 | 10.00 | 3.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 111 | - | - | - | 178 | - | - | - | 60.00 | - | - | - | 49.00 | - | - | - | 26.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -103.8% | -19,653 | -9,644 | -11,951 | -16,758 | -21,310 | -11,310 | -8,195 | -10,720 | -19,415 | -12,428 | -17,373 | -3,185 | 10,563 | -3,275 | -15,777 | 10,292 | -3,939 | -4,865 | -4,763 | -5,146 | -9,078 |
Share Based Compensation | 15.4% | 3,589 | 3,111 | 3,049 | 3,054 | 2,740 | 2,870 | 2,757 | 2,235 | 1,781 | 1,383 | 648 | 39.00 | 36.00 | -245 | 34.00 | 308 | 327 | -786 | 646 | 605 | 622 |
Cashflow From Investing | 189.3% | 10,555 | 3,649 | 12,667 | 50,561 | 16,329 | -84,379 | -48,243 | -241 | -23.00 | -46.00 | 25,356 | - | - | - | -6.83 | - | - | 1* | -4.28 | -119 | -113 |
Cashflow From Financing | -112.5% | -10.00 | 80.00 | -75.00 | 313 | 8.00 | -107 | 72,516 | -87.00 | 298 | 88.00 | 141,717 | -71.28 | 70.00 | - | - | - | - | - | - | - | - |
Dividend Payments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Total revenue | $ 5,353 | $ 5,867 |
Operating expenses | ||
Selling, general and administrative | 10,620 | 11,207 |
Research and development | 13,593 | 10,956 |
Cost of goods sold | 652 | 529 |
Total operating expenses | 24,865 | 22,692 |
Loss from operations | (19,512) | (16,825) |
Other income (expense) | ||
Foreign exchange loss | (1) | 0 |
Interest income | 1,282 | 1,660 |
Interest expense | (58) | (58) |
Total other income (expense), net | 1,223 | 1,602 |
Net loss | (18,289) | (15,223) |
Other comprehensive (loss) income: | ||
Unrealized (loss) income on available-for-sale debt securities | (35) | 83 |
Comprehensive loss | $ (18,324) | $ (15,140) |
Net loss per share, basic (in dollars per share) | $ (0.68) | $ (0.57) |
Net loss per share, diluted (in dollars per share) | $ (0.68) | $ (0.57) |
Weighted average number of common shares outstanding, basic (in shares) | 26,980,698 | 26,862,646 |
Weighted average number of common shares outstanding, diluted (in shares) | 26,980,698 | 26,862,646 |
Product sales, net | ||
Total revenue | $ 5,353 | $ 5,867 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 53,780 | $ 62,888 |
Short-term investments | 34,491 | 45,957 |
Accounts receivable, net | 4,933 | 5,488 |
Inventory | 5,936 | 6,427 |
Prepaid expenses and other current assets | 3,433 | 3,826 |
Total current assets | 102,573 | 124,586 |
Property and equipment, net | 5,686 | 4,802 |
Operating lease right-of-use assets | 1,077 | 1,169 |
Other assets | 1,737 | 1,866 |
Total assets | 111,073 | 132,423 |
Current liabilities: | ||
Accounts payable | 3,095 | 5,898 |
Accrued liabilities | 10,598 | 14,306 |
Operating lease liabilities, current portion | 425 | 434 |
Due to licensor payable (Note 7) | 5,757 | 5,757 |
Total current liabilities | 19,875 | 26,395 |
Operating lease liabilities, net of current portion | 738 | 833 |
Total liabilities | 20,613 | 27,228 |
Commitments and contingencies (Note 12) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.0001 par value; 300,000,000 shares authorized; 24,554,205 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 2 | 2 |
Additional paid-in capital | 377,718 | 374,129 |
Accumulated other comprehensive (loss) income | (8) | 27 |
Accumulated deficit | (287,252) | (268,963) |
Total stockholders’ equity | 90,460 | 105,195 |
Total liabilities and stockholders’ equity | $ 111,073 | $ 132,423 |
Common stock, shares issued (in shares) | 24,554,205 | 24,554,205 |
Common stock, shares outstanding (in shares) | 24,554,205 | 24,554,205 |